Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization- challenge model

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1338-1354

  Hota Mitchell, Sheela ^a,b   Clarke, Michael W ^b   Podesta, R B ^b   Dekaban, Gregory A ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Calpain; DNA immunization; Gene gun; Recombinant vaccinia virus; Schistosoma mansoni; Vaccine

Indexed keywords

CALPAIN; DNA VACCINE; IMMUNOGLOBULIN G; SCHISTOSOMA VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME SUBUNIT; GENE GUN; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOPROPHYLAXIS; INTERMETHOD COMPARISON; INTRADERMAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; TREATMENT OUTCOME; VACCINATION; VACCINIA VIRUS;

ANIMALS; ANTIGENS, HELMINTH; BIOLISTICS; CALPAIN; CELL LINE; GENETIC VECTORS; MICE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; VACCINES, DNA; VACCINIA VIRUS;

EID: 0033577346     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00391-0     Document Type: Article

References (61)

1. WHO. The world health report 1996: fighting disease, fostering development. Geneva: The World Health Organization, 1996. p. 24.
2. Bergquist N.R. Controlling schistosomiasis by vaccination: a realistic option? Parasitol Today. 11:1995;191-196.
3. Bergquist N.R., Hall B.F., James S. Schistosomiasis vaccine development: translating basic research into practical results. Immunologist. 2:1994;13-16.
4. Dunne D.W., Hagan P., Abath F.G.C. Prospects for immunological control of schistosomiasis. Lancet. 345:1995;1488-1492.
5. Wright M.D., Davern K.M., Mitchell G.F. The functional and immunological significance of some schistosome surface molecules. Parasitol. Today. 7:1991;56-58.
6. Smithers S.R., Hackett F., Ali P.O., Simpson A.J.G. Protective immunization of mice against Schistosoma mansoni with purified adult worm surface membrane. Parasite Immunol. 11:1989;301-318.
7. Harn DA, Reynolds SR, Chikunguwo S, Furlong S, Dahl C. Synthetic peptide vaccines for schistosomiasis. In: Powell MF, Newman MJ, editors. Vaccine Design: the Subunit and Adjuvant Approach. New York: Plenum Press, 1995. p. 891-905.
8. Andresen K., Tom T.D., Strand M. Characterization of cDNA clones encoding a novel calcium-activated neutral proteinase from Schistosoma mansoni. J Biol Chem. 266:1991;15085-15090.
9. Karcz S.R., Podesta R.B., Siddiqui A.A., Dekaban G.A., Strejan G.H., Clarke M.W. Molecular cloning and sequence analysis of a calcium-activated neutral protease (calpain) from Schistosoma mansoni. Mol Biochem Parasitol. 49:1991;333-336.
10. Hota-Mitchell S., Siddiqui A.A., Dekaban G.A., Smith J., Tognon C., Podesta R.B. Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. Vaccine. 15:1997;1631-1640.
11. Siddiqui A.A., Zhou Y., Podesta R.B.et al. Characterization of Ca2+-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta. 1181:1993;37-44.
12. Podesta R, Karcz S, Ansell M, Silva E. Schistosoma mansoni: apical membrane/envelope synthesis, signal transduction and protein phosphorylation. In: Liss AR, editor, Molecular Paradigms for Eradicating Helminthic Parasites 1987. p. 241-55.
13. Jankovic D., Aslund L., Oswald I.P.et al. Calpain is the target antigen of a Th1 clone that transfers protective immunity against Schistosoma mansoni. J Immunol. 157:1996;806-814.
14. Sorimachi H., Toyama-Sorimachi N., Saido T.C.et al. Muscle-specific calpain, p94, Is degraded by autolysis immediately after translation, resulting in disappearance from muscle. J Biol Chem. 268:1993;10593-10605.
15. Croall D.E., Demartino G.N. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol Rev. 71:1991;813-847.
16. Moss B. Vaccinia virus: a tool for research and vaccine development. Science. 252:1991;1662-1667.
17. Shirai M., Okada H., Nishioka M.et al. An epitope in hepatitis C virus core region recognized by cytotoxic T-cells in mice and humans. J Virol. 68:1994;3334-3342.
18. Jonjic S., del Val M., Keil G.M., Reddehase M.J., Koszinowski U.H. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol. 62:1988;1653-1658.
19. Earl P.L., Moss B., Morrison R.P., Wehrly K., Nishio J., Chesebro B. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science. 234:1986;728-731.
20. Johnson R.P., Hammond S.A., Trocha A., Siliciano R.F., Walker B.D. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J Virol. 68:1994;3145-3153.
21. Fonseca B.A.L., Pincus S., Shope R.E., Paoletti E., Mason P.W. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine. 12:1994;279-285.
22. Chu Y.-K., Jennings G.B., Schmaljohn C.S. A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus. J Virol. 69:1995;6417-6423.
23. Smith G.L., Mackett M., Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature. 302:1983;490-495.
24. Moelans I.I.M.D., Cohen J., Marchand M.et al. Induction of Plasmodium falciparum sporozoite-neutralizing antibodies upon vaccination with recombinant Pfs16 vaccinia virus and/or recombinant Pfs16 protein produced in yeast. Mol Biochem Parasitol. 72:1995;179-192.
25. Hassett D.E., Whitton J.L. DNA immunization. Trends Microbiol. 4:1996;307-312.
26. Ertl H.C.J., Xiang Z. Novel vaccine approaches. J Immunol. 156:1996;3579-3582.
27. Manickan E., Karem K.L., Rouse B.T. DNA vaccines: a modern gimmick or a boon to vacciniology? Crit Rev Immunol. 17:1997;139-154.
28. Leong KH, Ramsay AJ, Ramshaw IA, Morin MJ, Robinson HL, Boyle DB. Generation of enhanced immune responses by consecutive immunization with DNA and recombinant fowl pox vectors. In: Chanock RM, Brown F, Ginsberg HS, editors. Vaccines 95: Molecular Approaches to the Control of Infectious Diseases. Plainview, New York: Cold Spring Harbor Laboratory Press, 1995. p. 327-31.
29. Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: coexpression of B-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol. 5:1985;3403-3409.
30. Dales S., Siminovitch L. The development of vaccinia virus in Earle's L strain cells as examined by electron microscopy. J Biophys Biochem Cytol. 10:1961;475-503.
31. Joseph A.L., Boros D.L. Tumor necrosis factor plays a role in Schistosoma mansoni egg-induced granulomatous inflammation. J Immunol. 151:1993;5461-5471.
32. Smithers S.R., Terry R.J. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms. Parasitology. 55:1965;695-700.
33. McDiarmid S.S., Dean L.L., Podesta R.B. Sequential removal of outer bilayer and apical plasma membrane from the surface epithelial syncytium of Schistosoma mansoni. Mol Biochem Parasitol. 7:1983;141-157.
34. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell. 44:1986;283-292.
35. Sambrook J, Fritsch EF, Maniatis T. Site-directed mutagenesis of cloned DNA. In: Molecular Cloning: a Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989. p. 15.51-.56.
36. Mahvi D.M. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Human Gene Ther. 7:1996;1535-1543.
37. Condon C., Watkins S.C., Celluzzi C.M., Thompson K., Falo L.D. Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nature Med. 2:1996;1122-1128.
38. Ford C.M., Arp J., Palker T.J., King E.E., Dekaban G.A. Characterization of the antibody response to three different versions of the HTLV-I envelope protein expressed by recombinant vaccinia viruses: induction of neutralizing antibody. Virology. 191:1992;448-453.
39. Weisz OA, Machamer CE. Use of recombinant vaccinia virus vectors for cell biology. In: Roth MG, editor. Methods in Cell Biology: Protein Expression in Animal Cells. San Diego: Academic Press, 1994. p. 137-59.
40. Joklik W.K. The purification of four strains of poxvirus. Virology. 18:1962;9-18.
41. Schagger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 166:1987;368-379.
42. Johnson D.A., Gautsch J.W., Sportsman J.R., Elder J.H. Improved technique utilizing nonfat dry milk for analysis of proteins and nucleic acids transferred to nitrocellulose. Gen Anal Techn Appl. 1:1984;3-8.
43. Zar JH. Data transformations. In: Biostatistical Analysis. New Jersey: Prentice-Hall, 1984. p. 236-43.
44. Montgomery DC. Experiments with a single factor: the analysis of variance. In: Design and Analysis of Experiments. New York: John Wiley and Sons, 1997. p. 50-94.
45. Hayes K., Weaver L.C. Selective control of sympathetic pathways to the kidney, spleen and intestine by the ventrolateral medulla in rats. J Physiol. 428:1990;371-385.
46. Krassioukov A.V., Gelb A.W., Weaver L.C. Actions of propofol on pontine neurons controlling arterial pressure in rats. Can J Anaesthesia. 42:1995;150-157.
47. Sokal RR, Rohlf FJ. Assumptions of analysis of variance. In: Biometry: the Principles and Practice of Statistics in Biological Research. San Francisco: W.H. Friedman and Company, 1969. p. 367-403.
48. Zar JH. Multiple comparisons. In: Biostatistical Analysis. New Jersey: Prentice-Hall, 1984. p. 185-205.
49. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA. 3:1996;11341-11348.
50. Waine G.J., McManus D.P. Schistosomiasis vaccine development: the current picture. BioEssays. 19:1997;435-443.
51. Nesburn A.B., Slanina S., Burke R.L., Ghiasi H., Bahri S., Wechsler S.L. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol. 72:1998;7715-7721.
52. Choi T., Huang M., Gorman C., Jaenisch R. A generic intron increases gene expression in transgenic mice. Mol Cell Biol. 11:1991;3070-3074.
53. Wilson R.A., Coulson P.S. Lung-phase immunity to schistosomes: a new perspective on an old problem. Parasitol Today. 5:1989;274-282.
54. Dean D.A., Mangold B.L. Evidence that both normal and immune elimination of Schistosoma mansoni take place at the lung stage of migration prior to parasite death. Am J Trop Med. Hygiene. 47:1992;238-248.
55. Rooney J.F., Wohlenberg C., Cremer K.J., Moss B., Notkins A.L. Immunization with a vaccinia virus recombinant expressing Herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol. 62:1988;1530-1534.
56. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immuniziation. J Immunol. 158:1997;2278-2284.
57. Pertmer T.M., Roberts T.R., Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol. 70:1996;6119-6125.
58. + T-cells. J Virol. 69:1995;4711-4716.
59. Richter D., Incani R.N., Harn D.A. Isotype responses to candidate vaccine antigens in protective sera obtained form mice vaccinated with irradiated cercariae of Schistosoma mansoni. Infect Immun. 61:1993;3003-3011.
60. Mazza G., Dunne D.W., Butterworth A.E. Antibody isotype responses to the Schistosoma mansoni schistosomulum in the CBA/N moused induced by different stages of the parasite life cycle. Parasite Immunol. 12:1990;529-543.
61. Robinson H.L., Lu S., Feltquate D.M.et al. DNA vaccines. AIDS Res Human Retroviruses. 12:1996;455-457.